WHOOP secures $575 million with a valuation of $10.1 billion, indicating a potential IPO on the horizon.

      In summary, WHOOP has successfully secured $575 million in a Series G funding round, valuing the screenless health wearable company at $10.1 billion—almost three times its 2021 valuation. Supported by sovereign wealth funds, prominent medical institutions, and a lineup of celebrity athletes, the Boston-based startup is gearing up for an initial public offering (IPO). According to its founder and CEO, this upcoming private round will be the last.

      Founded in 2012 by Ahmed, a student-athlete from Harvard, John Capodilupo, and Aurelian Nicolae, WHOOP has been incubated at the Harvard Innovation Labs. The company’s primary product is distinguished by its absence of a screen; unlike devices such as the Apple Watch, Fitbit, or Garmin's offerings, WHOOP does not display step counts or notifications. Instead, it continuously tracks strain, recovery, and sleep, providing users with insights into their physiological choices through an app.

      The funding round, concluded on March 31, 2026, was led by Collaborative Fund and attracted a diverse group of backers, including major investors like Mubadala Investment Company and the Qatar Investment Authority, in addition to institutions such as Abbott and the Mayo Clinic. High-profile individual investors include Cristiano Ronaldo, LeBron James, Rory McIlroy, Reggie Miller, and musician Niall Horan. This combination signals WHOOP’s transition from solely a fitness gadget maker to a broader personal health platform.

      The company boasts a membership of over 2.5 million and ended 2025 with a bookings run rate of $1.1 billion, reflecting a year-on-year growth of 103%. Notably, women's membership grew by 150% year-on-year, with female users engaging more with WHOOP's AI features compared to male users, informing the company’s product and marketing strategies.

      In May 2025, WHOOP launched its 5.0 model and its first medical-grade device, WHOOP MG, which features an FDA-cleared electrocardiogram, blood pressure insights, and a Healthspan estimation. In September 2025, it introduced the Advanced Labs service, allowing members to combine blood testing with wearable data analysis, with curated biomarker panels reviewed by a clinician.

      As WHOOP scales, it plans to hire over 600 roles globally, merging investments in talent with advancements in AI tools. The Series G funding will facilitate domestic growth in the U.S. and international expansion into Europe, the Gulf Cooperation Council, Latin America, and Asia.

      While Ahmed has not specified an exact IPO date, he has indicated the company is preparing for a public listing. Given its current valuation of $10.1 billion, WHOOP is now valued at approximately a quarter of Garmin, which operates across various product categories. Future investor perception of WHOOP’s platform ambitions and its integration of continuous biometric data with periodic blood testing will be critical in determining its market position over the coming years.

      The largest funding rounds in 2026 highlight companies that present their products as not merely AI tools but as essential infrastructures, a claim that WHOOP is beginning to make regarding personal health data. Ahmed succinctly summarized the significance of the $575 million round: it aims to establish a platform that promotes health and build public market credibility to support that goal. WHOOP’s decade-long collection of member data, partnership with Mayo Clinic, and subscription-based business model may give it an edge over competitors.